JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...

JCR announced that it has entered into a license agreement with Alexion, for JCR’s new, proprietary JUST-AAV capsids to ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

Annexon offers speculative upside with Tanruprubart, targeting Guillain-Barré Syndrome's unmet needs. Click here to read my ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

JCR Pharma signs agreement with Alexion for proprietary JUST-AAV capsids to develop genomic medicines: Hyogo, Japan Thursday, July 10, 2025, 10:00 Hrs [IST] JCR Pharmaceuticals Co ...

Alexion Charitable Foundation announced it is giving the substantial grant to Roald Dahl's Marvellous Children's Charity.

The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

Alexion, AstraZeneca Rare Disease, will present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at the European Academy of Neurology (EAN) Annual Congress ...

French biotech Inventiva has changed up its executive team as it continues to bet on experimental MASH therapy lanifibranor, ...

Merck & Co. Inc. has strengthened its cardiopulmonary pipeline with its $10 billion acquisition of London-based-Verona Pharma plc. The deal brings Merck Ohtuvayre (ensifentrine) for chronic ...

AI is fundamental to the competitive strategies of the most advanced healthcare and pharmaceutical firms. Here is how they ...